HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrew X Zhu Selected Research

Ramucirumab

1/2022Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials.
11/2021Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.
9/2021Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).
6/2021Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α-fetoprotein: Outcomes by treatment-emergent ascites.
1/2021Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.
1/2021Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.
8/2020Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies.
6/2020Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
1/2020Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
1/2020Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrew X Zhu Research Topics

Disease

126Hepatocellular Carcinoma (Hepatoma)
06/2022 - 11/2004
117Neoplasms (Cancer)
06/2022 - 06/2003
38Cholangiocarcinoma
01/2022 - 01/2004
17Biliary Tract Neoplasms (Biliary Tract Cancer)
10/2021 - 02/2008
16Liver Neoplasms (Liver Cancer)
10/2020 - 08/2007
15Fibrosis (Cirrhosis)
01/2021 - 01/2009
14Adenocarcinoma
11/2021 - 01/2005
13Pancreatic Neoplasms (Pancreatic Cancer)
07/2019 - 10/2004
12Colorectal Neoplasms (Colorectal Cancer)
11/2021 - 02/2004
11Hypertension (High Blood Pressure)
01/2022 - 06/2004
11Liver Diseases (Liver Disease)
11/2021 - 12/2013
10Disease Progression
11/2021 - 01/2012
10Neoplasm Metastasis (Metastasis)
11/2018 - 01/2009
7Fatigue
01/2021 - 04/2006
6Ascites
11/2021 - 07/2015
6Carcinoma (Carcinomatosis)
12/2020 - 02/2004
6Diarrhea
12/2019 - 04/2006
6Neuroendocrine Tumors (Neuroendocrine Tumor)
09/2013 - 06/2006
5Rectal Neoplasms (Rectal Cancer)
01/2021 - 10/2003
5Renal Cell Carcinoma (Grawitz Tumor)
01/2020 - 07/2006
5Neutropenia
01/2010 - 04/2006
4Hypoxia (Hypoxemia)
01/2022 - 11/2011
3Asthenia
08/2020 - 07/2014
3Thrombosis (Thrombus)
05/2020 - 01/2012
3Gastrointestinal Neoplasms (Gastrointestinal Cancer)
01/2020 - 01/2012
3Vomiting
12/2019 - 04/2006
3Nausea
12/2019 - 04/2006
3Thrombocytopenia (Thrombopenia)
07/2015 - 11/2006
2Inflammation (Inflammations)
01/2022 - 12/2020
2Thrombotic Microangiopathies
05/2021 - 06/2004
2Pain (Aches)
01/2021 - 01/2020
2Weight Loss (Weight Reduction)
01/2020 - 11/2006
2Carcinogenesis
01/2020 - 11/2006
2Liver Failure
01/2019 - 01/2018
2Lung Neoplasms (Lung Cancer)
01/2019 - 11/2006

Drug/Important Bio-Agent (IBA)

37Sorafenib (BAY 43-9006)FDA Link
04/2022 - 01/2008
33Biomarkers (Surrogate Marker)IBA
06/2022 - 11/2005
20RamucirumabIBA
01/2022 - 12/2013
17Bevacizumab (Avastin)FDA Link
04/2022 - 02/2004
17GemcitabineFDA Link
10/2021 - 06/2004
12Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 02/2004
11alpha-Fetoproteins (alpha-Fetoprotein)IBA
01/2022 - 07/2009
11Oxaliplatin (Eloxatin)FDA LinkGeneric
07/2019 - 04/2006
10Pharmaceutical PreparationsIBA
01/2022 - 06/2003
10Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
01/2022 - 01/2012
10Irinotecan (Camptosar)FDA LinkGeneric
07/2019 - 04/2006
9atezolizumabIBA
04/2022 - 01/2020
9RNA (Ribonucleic Acid)IBA
01/2022 - 12/2015
8Protons (Proton)IBA
04/2020 - 07/2014
8Fluorouracil (Carac)FDA LinkGeneric
07/2019 - 02/2004
8ErbB Receptors (EGF Receptor)IBA
07/2016 - 05/2006
7pembrolizumabIBA
01/2022 - 01/2018
7AlbuminsIBA
09/2021 - 10/2014
7Tyrosine Kinase InhibitorsIBA
01/2021 - 05/2006
7Proteins (Proteins, Gene)FDA Link
07/2016 - 11/2006
7EverolimusFDA Link
01/2016 - 11/2011
7Sunitinib (Sutent)FDA Link
08/2014 - 01/2009
6Aspartate Aminotransferases (Aspartate Transaminase)IBA
01/2022 - 08/2007
6Leucovorin (Folinic Acid)FDA Link
07/2019 - 02/2004
6Phosphotransferases (Kinase)IBA
01/2019 - 01/2009
6Biological ProductsIBA
07/2018 - 10/2003
5Alanine Transaminase (SGPT)IBA
01/2022 - 01/2010
5Immune Checkpoint InhibitorsIBA
11/2021 - 11/2014
5Fetal Proteins (Fetoprotein)IBA
06/2021 - 01/2012
5Cytidine Triphosphate (CTP)IBA
01/2018 - 02/2008
4ivosidenibIBA
11/2021 - 01/2019
4infigratinibIBA
10/2021 - 01/2017
4Cisplatin (Platino)FDA LinkGeneric
12/2020 - 06/2006
4Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
01/2020 - 07/2009
4Capecitabine (Xeloda)FDA Link
07/2019 - 04/2006
4folfirinoxIBA
07/2019 - 01/2013
4Erlotinib Hydrochloride (CP 358,774)FDA Link
10/2016 - 04/2006
4DNA (Deoxyribonucleic Acid)IBA
01/2016 - 12/2015
4Cetuximab (Erbitux)FDA Link
01/2012 - 05/2006
3Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2022 - 01/2009
3BilirubinIBA
09/2021 - 07/2015
3Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA
01/2021 - 07/2016
3Monoclonal AntibodiesIBA
06/2019 - 01/2012
3Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
01/2019 - 01/2011
3AntigensIBA
03/2014 - 01/2005
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2022 - 10/2016
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2022 - 01/2017
2cabozantinibIBA
01/2022 - 01/2017
2Circulating Tumor DNAIBA
01/2021 - 01/2017
2Indicators and Reagents (Reagents)IBA
01/2021 - 10/2014
2lenvatinibIBA
12/2020 - 10/2020
2Programmed Cell Death 1 ReceptorIBA
11/2020 - 01/2020
2Cell-Free Nucleic AcidsIBA
01/2019 - 01/2017

Therapy/Procedure

92Therapeutics
01/2022 - 06/2003
28Drug Therapy (Chemotherapy)
01/2022 - 06/2003
22Radiotherapy
11/2021 - 01/2005
9Immunotherapy
01/2022 - 01/2005
7Neoadjuvant Therapy
01/2021 - 06/2012
6Liver Transplantation
01/2019 - 11/2004
6Aftercare (After-Treatment)
01/2018 - 05/2006
5Proton Therapy
01/2018 - 07/2014
4Radiofrequency Ablation
04/2015 - 04/2008
3Adjuvant Chemotherapy
01/2018 - 08/2010
3Surgical Instruments (Clip)
12/2013 - 08/2007
2Chemoradiotherapy
07/2019 - 01/2018